Skip to content

Serotonin: all studies

Page 382 of 400: studies 3,811 to 3,820 of 3,999, newest first. Back to the serotonin overview

Research

LSD: A missed opportunity?

Human Psychopharmacology: Clinical and Experimental September 1, 1994 Gordon Claridge 11 citations

Abstract Despite its early promise as ‘the chemical key to schizophrenia’, and its manifest properties as a psychotomimetic, LSD failed to catch on as a drug model for human psychosis. The reasons for this and the longstanding preference, instead, for the amphetamine model are examined. It is argued that the rejection of LSD was not just a scientific decision, but was influenced by increasing...

DOI: 10.1002/hup.470090504 (opens in new tab) Lysergic acid diethylamide Schizophrenia object-oriented programming Psychotomimetic Hallucinogen +4

MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac).

Neuropsychopharmacology July 1994 E T Leonardi, Efrain C. Azmitia

3,4-Methylenedioxymethamphetamine (MDMA), a serotonin (5-HT) neurotoxin, has been shown to promote the release of serotonin (5-HT) and block its reuptake. The increased buildup of extracellular 5-HT should normally be degraded by monoamine oxidase (MAO). The effects of both enantiomers of MDMA were examined on MAO-A and monoamine oxidase-B (MAO-B) activity in rat brain homogenates. Both...

Chronic 3,4-methylenedioxymethamphetamine administration decreases glucocorticoid and mineralocorticoid receptor, but increases 5-hydroxytryptamine1C receptor gene expression in the rat hippocampus.

Neuroscience July 1994 J L Yau, P A Kelly, J Sharkey et al.

Both glucocorticoids and serotonin have been implicated in the regulation of mood and neuroendocrine control. In this study we have examined the effects of the psychomotor stimulant, 3,4-methylenedioxymethamphetamine on corticosteroid and 5-hydroxytryptamine receptor subtype gene expression within the hippocampal formation using in situ hybridization histochemistry. Animals were injected...

Binding sites for 5-hydroxytryptamine-2 receptor agonists are predominantly located in striosomes in the human basal ganglia.

Brain research. Molecular brain research July 1994 C Waeber, J M Palacios

Previous autoradiographic studies have shown that serotonin 5-HT2 receptors are homogeneously distributed in the human striatum. While these studies were done using antagonist radioligands such as [3H]ketanserin, we describe here a heterogeneous distribution of 5-HT2 binding sites in the human striatum, using [3H]LSD and [125I]DOI as ligands. Beside their agonist properties, these compounds...

Blockade of Striatal 5‐Hydroxytryptmine2Receptors Reduces the Increase in Extracellullar Concentrations of Dopamine Produced by the Amphhetamine analogue 3,4‐Methylenedioxymethamphetamine

Journal of Neurochemistry April 1, 1994 Christopher J. Schmidt, C. K. Sullivan, G. M. Fedayal 130 citations

5-Hydroxytryptamine2 (5-HT2) receptor antagonists have been shown to interfere with the stimulation of striatal dopamine synthesis and release produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine (MDMA). To localize the receptors responsible for the attenuation of MDMA-induced release, 5-HT2 receptor antagonists were infused via the microdialysis probe directly into the brains...

In vitro release of [3H]5-hydroxytryptamine from fetal and maternal brain by drugs of abuse.

Brain research. Developmental brain research March 18, 1994 K Kramer, E C Azmitia, P M Whitaker-Azmitia

Cortical synaptosomes were prepared from pregnant dams (GD-17) and rat fetuses (ED-17), loaded with [3H]5-HT and assayed to evaluate release mediated by cocaine (COC), fenfluramine (FEN) and 3,4-methylenedioxymethamphetamine (MDMA). COC and FEN elicited a high-affinity (10(-9) M) release response in fetal tissue which was not apparent in the dam. MDMA-induced release was similar in magnitude in...

Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects.

Archives of General Psychiatry February 1, 1994 R J Strassman, C R Qualls

Background: To begin applying basic neuropharmacological hypotheses of hallucinogenic drug actions to humans, we generated dose-response data for intravenously administered dimethyltryptamine fumarate's (DMT) neuroendocrine, cardiovascular, autonomic, and subjective effects in a group of experienced hallucinogen users. Methods: Dimethyltryptamine, an endogenous mammalian hallucinogen and drug...

DOI: 10.1001/archpsyc.1994.03950020009001 (opens in new tab) Cardiovascular system Autonomic nervous system Pupil Humans +15

RTI-4793-14, a new ligand with high affinity and selectivity for the (+)-MK801-insensitive [3H]1-]1-(2-thienyl)cyclohexyl]piperidine binding site (PCP site 2) of guinea pig brain.

Synapse 1994 C B Goodman, D N Thomas, A Pert et al.

[3H]TCP, an analog of the dissociative anesthetic phencyclidine (PCP), binds with high affinity to two sites in guinea pig brain membranes, one that is MK-801 sensitive and one that is not. The MK-801-sensitive site (PCP site 1) is associated with NMDA receptors, whereas the MK-801-insensitive site (PCP site 2) may be associated with biogenic amine transporters (BAT). Although several "BAT...

Potentiation of 5‐methoxy‐n,n‐dimethyltryptamine‐induced head‐twitches by diazepam: Evidence for involvement of adenosine uptake inhibition

Drug Development Research December 1, 1993 Paul C. Moser

AbstractPrevious work shows that benzodiazepines potentiate head‐twitches induced by 5‐HT agonists and that this action is not mediated via the GABA receptor complex. In the present study the involvement of adenosinergic mechanisms in this effect has been examined, as in addition to their actions at the GABA receptor, benzodiazepines also inhibit adenosine uptake. The adenosine antagonists...

Comparison of the behavioral effects of ibogaine from three sources: mediation of discriminative activity.

European Journal of Pharmacology November 2, 1993 M D Schechter, T L Gordon 33 citations

Ibogaine is an alkaloid employed for its hallucinatory properties in West Central Africa which has been the subject of alleged efficacy as an aid in the interruption and treatment of chemical dependency. The major sources of the Schedule I agent are: Sigma Chemical Co., the National Institute on Drug Abuse and as NDA International Inc.'s Endabuse. The intent of the present study was to, for the...